How Can Myeloma Patients Facing Disparities Be More Proactive in Their Care?

 

More Programs and Publications Featuring Dr. Victoria Vardell

In this program:

Dr. Victoria Vardell of the Huntsman Cancer Institute of Utah discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT) and encourages patients to ask questions of their providers until they have a complete understanding.

Read Transcript

Dr. Victoria Vardell:
Multiple Myeloma is as an interesting disease in that it is much more likely to impact Black patients, which is one reason it's interesting to find that Black patients are less likely to receive stem cell transplants and other upfront therapies that are highly recommended.

One of the best things that patients can do is always ask questions. It's easy as physicians to think that someone is understanding what you're saying or understanding what you've known for years, but Multiple Myeloma and many cancers are very confusing and complex diseases. And the therapies are becoming more and more complex as well, so patients can benefit a lot from asking questions, not being afraid to ask them multiple times until they are fully understanding it. And also finding out what resources are available. At many of these large cancer institutes, the resources available for patients are very large, we are always very happy to educate our patients and that's the best way that they can make educated decisions going forward in their treatment.

In retaining editorial control, the information produced by Diverse Health Hub does not encapsulate the views of our sponsors, contributors, or collaborators.

Importantly, this information is not a substitute for, nor does it replace professional medical advice, diagnosis, or treatment. If you have any concerns or questions about your health, you should always consult with a healthcare professional. To learn more about privacy, read our 
Privacy Policy.

Related Videos:

Previous
Previous

Multinational CASiRe - Will Emerging Tools Harmonize Treatment for Sickle Cell Disease Patients?

Next
Next

Does Treatment Adherence in Myeloma Impact Outcomes?